enVVeno Medical (NVNO) Stock Price, News & Analysis

Company Overview

enVVeno Medical Corp. is a clinical-stage medical device company focused on developing bioprosthetic implants for the treatment of venous and cardiovascular diseases. The company’s primary focus is chronic venous insufficiency, a condition in which damaged valves in the veins impair the return of blood to the heart and can cause swelling, pain, skin changes and ulcers.

Its lead product candidate, the VenoValve, is a surgically implanted bioprosthetic venous valve designed to restore one-way blood flow in the deep veins of the lower extremities. The company has also been developing additional valve technologies intended to address unmet needs in the treatment of venous disease. These products are investigational and subject to regulatory review and approval.

enVVeno Medical was formerly known as Hancock Jaffe Laboratories and adopted its current name in 2021 to reflect its emphasis on venous disease and valve replacement technologies. The company is headquartered in Nashville, Tennessee, and operates as a development-stage medical technology business serving the healthcare market.

Key Stats

• Today's Range: $8.01 to $9.41
• 50-Day Range: $7.80 to $11.80
• 52-Week Range: $7.01 to $35.17
• Volume: 23,787 shs
• Average Volume: 18,412 shs
• Market Capitalization: $5.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

enVVeno Medical Stock Analysis - MarketRank™

enVVeno Medical scored higher than 37% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.8 / 5
• Analyst Rating: Hold

Consensus Rating

enVVeno Medical has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

enVVeno Medical has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for enVVeno Medical are expected to grow in the coming year, from ($16.19) to ($6.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of enVVeno Medical is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of enVVeno Medical is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

enVVeno Medical has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.59% of the float of enVVeno Medical has been sold short.

Short Interest Ratio / Days to Cover

enVVeno Medical has a short interest ratio ("days to cover") of 0.24, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in enVVeno Medical has recently increased by 11.08%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

enVVeno Medical does not currently pay a dividend.

Dividend Growth

enVVeno Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

enVVeno Medical has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for enVVeno Medical this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, enVVeno Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $123.00 in company stock.

Percentage Held by Insiders

15.00% of the stock of enVVeno Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

34.71% of the stock of enVVeno Medical is held by institutions.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 10/01/2026
• Next Earnings (Estimated): 10/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:NVNO
• CIK: 1661053
• Web: www.envveno.com
• Phone: (949) 261-2900
• Fax: 949-261-2992
• Employees: 33
• Year Founded: 1987

Profitability

• EPS (Trailing Twelve Months): ($19.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.47 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -62.28%
• Return on Assets: -56.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.70
• Quick Ratio: 11.70

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $41.38 per share
• Price / Book: 0.20

Miscellaneous

• Outstanding Shares: 690,000
• Free Float: 591,000
• Market Cap: $5.64 million
• Optionable: No Data
• Beta: 1.06